Table I:
Baseline Characteristics
| Variablea | All Subjects (N=1840) | Blacks (N=450) | Non-Hispanic Whites (N=1108) |
|---|---|---|---|
| Age (years) | 36 (12) | 37 (12) | 36 (12) |
| Sex (n [%male]) | 665 (36%) | 110 (24%) | 667 (60%) |
| BMI | 29 (7.7) | 32 (9.2) | 27 (6.6) |
| Subgroup with genotyping | 787 | 165 | 510 |
|
Ancestry median (Q1,Q3): % African % European % Native American |
2% (0.3%, 14.7%); 97% (54.7%, 99.1%); 1% (0.2%, 1.9%) |
82% (71%, 87%); 16% (11%, 26%); 1% (1%, 2%) |
0% (0%, 2%); 99% (98%, 99%); 0% (0%, 1%) |
| oral steroid bursts in prior 12 months | 0.36 (0.82) | 0.61 (1.1) | 0.27 (0.65) |
| FEV1%predicted | 82% (15%) | 80% (14%) | 84% (15%) |
| PC20, geometric mean (CV)b | 1.54 (1.31) | 1.35 (1.36) | 1.60 (1.29) |
| %BD reversibility post 4 albuterol puffsc | 12% (9.4%) | 13% (11%) | 12% (9.0%) |
| ACQ6d | 0.96 (0.74) | 1.02 (0.88) | 0.95 (0.68) |
| Blood eos (absolute count/mm3), median (Q1, Q3)e | 198 (100, 300) | 178 (100, 295) | 200 (100, 300) |
| %Sputum eos, median (Q1, Q3)f | 0.4 (0.0, 1.7) | 0.4 (0.0, 1.7) | 0.4 (0.0, 1.6) |
| Serum IgE, median (Q1, Q3)g | 136 (51, 333) | 201 (83, 496) | 107 (43, 256) |
a
Baseline characteristics expression as a mean with standard deviation (SD) unless otherwise stated, including medians with interquartile ranges (Q1, Q3).
b
Methacholine PC20 available on 1,604 subjects (392 Blacks, 970 Whites).
c
Bronchodilator (BD) reversibility of FEV1 in response to four puffs of albuterol available on 1,363 subjects (450 Blacks, 807 Whites).
d
Asthma Control Questionairre-6 (ACQ-6) available on 1,035 subjects (233 Blacks, 640 Whites).
e
Blood eosinophil (eos) counts available on 967 subjects (216 Blacks, 587 Whites).
f
Sputum eosinophil (eos) percentages available on 1,291 subjects (286 Blacks, 808 Whites).
g
IgE Available on 983 subjects (212 Blacks, 605 Whites).